Nebraska will be getting a $3.2 million share of a $520 million federal settlement with pharmaceutical manufacturer AstraZeneca PLC.
The federal settlement resolved allegations of illegal marketing of the company's anti-psychotic drug Seroquel.
The office of Nebraska Attorney General Jon Bruning announced the settlement involving the Nebraska Medicaid program on Wednesday.
Bruning says the money reimburses the Nebraska Medicaid program.
Federal regulators say AstraZeneca marketed Seroquel for off-label uses - those not approved by federal drug regulators - including insomnia and psychiatric conditions other than schizophrenia and bipolar disorder.
AstraZeneca denied the allegations.
